Compare Elder Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA STRIDES PHARMA SCIENCE ELDER PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -0.2 14.8 - View Chart
P/BV x 0.1 0.9 11.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ELDER PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
STRIDES PHARMA SCIENCE
Mar-18
ELDER PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3801,147 33.1%   
Low Rs188642 29.3%   
Sales per share (Unadj.) Rs491.2317.2 154.8%  
Earnings per share (Unadj.) Rs-3.27.8 -40.6%  
Cash flow per share (Unadj.) Rs14.425.1 57.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs376.5274.3 137.3%  
Shares outstanding (eoy) m20.5489.50 22.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.62.8 20.5%   
Avg P/E ratio x-89.3114.0 -78.3%  
P/CF ratio (eoy) x19.735.7 55.2%  
Price / Book Value ratio x0.83.3 23.1%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m5,83380,058 7.3%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m2,1794,341 50.2%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m10,08928,394 35.5%  
Other income Rs m257941 27.3%   
Total revenues Rs m10,34629,334 35.3%   
Gross profit Rs m-7923,965 -20.0%  
Depreciation Rs m3611,540 23.5%   
Interest Rs m2,7561,962 140.5%   
Profit before tax Rs m-3,6531,403 -260.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m3,713-436 -851.9%   
Tax Rs m12597 128.6%   
Profit after tax Rs m-65702 -9.3%  
Gross profit margin %-7.814.0 -56.2%  
Effective tax rate %-3.46.9 -49.4%   
Net profit margin %-0.62.5 -26.2%  
BALANCE SHEET DATA
Current assets Rs m9,24024,836 37.2%   
Current liabilities Rs m9,99818,993 52.6%   
Net working cap to sales %-7.520.6 -36.5%  
Current ratio x0.91.3 70.7%  
Inventory Days Days4671 65.3%  
Debtors Days Days60113 52.9%  
Net fixed assets Rs m10,12434,289 29.5%   
Share capital Rs m206895 23.0%   
"Free" reserves Rs m5,58223,651 23.6%   
Net worth Rs m7,73424,546 31.5%   
Long term debt Rs m4,88915,513 31.5%   
Total assets Rs m22,88265,437 35.0%  
Interest coverage x-0.31.7 -19.0%   
Debt to equity ratio x0.60.6 100.0%  
Sales to assets ratio x0.40.4 101.6%   
Return on assets %11.84.1 288.8%  
Return on equity %-0.82.9 -29.5%  
Return on capital %22.36.9 323.6%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30715,697 2.0%   
Fx outflow Rs m125735 17.0%   
Net fx Rs m18114,962 1.2%   
CASH FLOW
From Operations Rs m11,7541,871 628.3%  
From Investments Rs m-5615,826 -9.6%  
From Financial Activity Rs m-6,762-10,157 66.6%  
Net Cashflow Rs m4,432-2,615 -169.5%  

Share Holding

Indian Promoters % 39.6 27.7 143.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 37.8 19.8%  
FIIs % 16.8 8.6 195.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 25.9 139.4%  
Shareholders   16,479 56,241 29.3%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  TORRENT PHARMA  SUVEN LIFESCIENCES  CIPLA  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS